id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15198 R62337 |
Cohen (Carbamazepine) (Mixed indications) (Controls unexposed, NOS), 2023 | Orofacial clefts | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 0.52 [0.13;2.09] | -/2,674 -/4,866,362 | - | 2,674 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10176 R46501 |
Blotière (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Oro-facial clefts | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
2.93 [0.54;16.06] C excluded (control group) |
2/512 4/2,997 | 6 | 512 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9766 R46480 |
Blotière (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 | Oro-facial clefts | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 2.61 [0.65;10.47] C | 2/512 2,815/1,875,733 | 2,817 | 512 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9678 R34452 |
Tomson (Carbamazepine), 2018 | Cleft lip or palate | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.86 [0.14;5.13] C | 2/1,957 3/2,514 | 5 | 1,957 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9655 R34367 |
Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 | Facial cleft | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.54 [0.46;13.86] C | 4/1,657 2/2,098 | 6 | 1,657 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9643 R34312 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Orofacial clefts | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick | Adjustment: No Partial overlapping | 1.22 [0.08;19.48] C | 1/685 1/833 | 2 | 685 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9625 R34224 |
Källén (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 | Orofacial cleft | early pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Partial overlapping |
0.72 [0.18;2.87] C excluded (control group) |
4/1,511 4/1,084 | 8 | 1,511 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9626 R34232 |
Källén (Carbamazepine) (Controls unexposed, NOS) (Indications NOS), 2013 | Orofacial cleft | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 1.26 [0.34;3.23] | 4/1,511 2,756/1,575,847 | 2,760 | 1,511 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9619 R34197 |
Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 | Oral cleft | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 1.08 [0.34;3.41] C | 5/1,033 7/1,562 | 12 | 1,033 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 7 studies | 1.23 [0.71;2.12] | 5,602 | 10,029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Mixed indications) (Controls unexposed, NOS; 2: Carbamazepine) (Controls unexposed NOS) (Mixed indications; 3: Carbamazepine; 4: Carbamazepine) (Controls exposed to Lamotrigine, sick; 5: Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications; 6: Carbamazepine) (Controls unexposed, NOS) (Indications NOS; 7: Carbamazepine) (Controls exposed to Lamotrigine, sick;
Asymetry test p-value = 0.8681 (by Egger's regression)
slope=0.0487 (0.9360); intercept=0.2225 (1.2729); t=0.1748; p=0.8681
excluded 9625, 10176